ADC Therapeutics price target raised to $8 from $6 at Stephens

Stephens raised the firm’s price target on ADC Therapeutics (ADCT) to $8 from $6 and keeps an Overweight rating on the shares. With data from LOTIS-5 and LOTIS-7 using Zylonta as a backbone therapy in combination for second-line diffuse large B-cell lymphoma, the firm views the second-line opportunity as becoming derisked, making the stock “highly underappreciated at these levels,” the analyst tells investors.